LONDON (Alliance News) - Scancell Holdings PLC Tuesday said it continues to be excited by data emerging from its ongoing phase I/2 clinical trial with its lead pipeline candidate SCIB1 in metastatic melanoma.
The company expects a final clinical study report for the trial in the first half of 2016, it said in a statement ahead of its annual general meeting.
All 20 patients with resected tumours at study entry remain alive, Scancell said.
Of the 16 patients who received 2-4 milligram doses of SCIB1 median survival since entry is 39 months, or 44 months since first diagnosis of metastatic disease, and only five patients have progressed. Of the four who have received an 8 milligram dose none have progressed, and median survival since entry is 7 months to date.
Elsewhere the company continued to progress the pre-clinical development of its pipeline candidate Modi-1, with first in man studies provisionally targeted for the fourth quarter of 2016.
"We look forward to communicating the findings from the final Clinical Study Report from our SCIB1 Phase 1/2 trial during the first half of 2016 and to progressing Modi-1 into the clinic towards the end of that year. While we continue to refine our roadmap for the future development of assets from both our platforms, we also continue to explore various options for the company that are consistent with maximising shareholder value," said joint Chief Executive Officer Richard Goodfellow in a statement.
Shares in Scancell were down 4.0% at 24.00 pence Tuesday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Scancell Holdings (SCLP)